Aligos Therapeutics (ALGS) Return on Sales (2021 - 2025)
Aligos Therapeutics' Return on Sales history spans 5 years, with the latest figure at 117.64% for Q4 2025.
- For Q4 2025, Return on Sales fell 9275.0% year-over-year to 117.64%; the TTM value through Dec 2025 reached 11.07%, up 974.0%, while the annual FY2025 figure was 11.07%, 2527.0% up from the prior year.
- Return on Sales reached 117.64% in Q4 2025 per ALGS's latest filing, down from 42.56% in the prior quarter.
- In the past five years, Return on Sales ranged from a high of 138.55% in Q1 2025 to a low of 163.96% in Q1 2023.
- Average Return on Sales over 5 years is 28.51%, with a median of 20.43% recorded in 2021.
- Peak YoY movement for Return on Sales: crashed -15011bps in 2023, then skyrocketed 18878bps in 2025.
- A 5-year view of Return on Sales shows it stood at 102.76% in 2021, then soared by 98bps to 1.57% in 2022, then plummeted by -782bps to 13.88% in 2023, then crashed by -79bps to 24.89% in 2024, then plummeted by -373bps to 117.64% in 2025.
- Per Business Quant, the three most recent readings for ALGS's Return on Sales are 117.64% (Q4 2025), 42.56% (Q3 2025), and 16.44% (Q2 2025).